ProCE Banner Activity

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Managing Immune Checkpoint Inhibitor–Related Toxicities: An Interactive Decision Support Tool

Tool

Use this mobile-friendly interactive algorithm tool to receive National Comprehensive Cancer Network® (NCCN®) guidance on optimal management of immune-related adverse events associated with immune checkpoint inhibitor therapy, adapted from the NCCN Guidelines for Management of Immunotherapy-Related Toxicities v1.2023.

Released: July 18, 2023

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, Eisai, Merck Sharp & Dohme LLC, and Regeneron Pharmaceuticals, Inc.

AstraZeneca

Eisai

Merck Sharp & Dohme, LLC

Regeneron Pharmaceuticals, Inc